Global Cardiac Biomarkers Market Report and Forecast 2024-2032

Global Cardiac Biomarkers Market Outlook

The global cardiac biomarkers market reached a value of about USD 11.35 billion in 2023. The market is further estimated to grow at a CAGR of 9.90% in the forecast period of 2024-2032 to reach a value of around USD 26.55 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Expanding Point of Care Testing Facility to Propel the Market Growth of Cardiac Biomarkers

Based on testing location, the point of care segment is expected to witness robust growth in the market of cardiac biomarkers over the forecast period. This could be attributed to the rising inclination towards point of care testing due to its potential to offer high sensitivity diagnosis. The improved patient management owing to rapid turnaround of results in a user-friendly manner without wasting time is accelerating the development of the market. The point of care offers high-quality biomarker measurements for diverse clinical settings, including acute care, outpatient clinics, clinical research centres, homes, rural areas, and the developing world. The point of care testing facilitates rapid treatment decisions and reduces the pressure on emergency departments. They enable widespread access to affordable cardiac diagnostics as it leads to reduction in overall hospital and laboratory facility costs.

Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cardiac biomarkers are used to diagnose critical heart conditions by evaluating the heart functioning of a patient. The biomarkers include enzymes, hormones or proteins that show up in the blood under severe stress or any injury and the test measure these cardiac biomarkers to find the seriousness of heart disease.

The market for cardiac biomarkers, by biomarker type, is divided into:

• Creatine Kinase -MB (CK-MB)
• Troponins (T and I)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

Based on indication, the market is segmented into:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

On the basis of end-user, the market is bifurcated into:

• Hospitals
• Speciality Clinics

Based on testing location, the market is divided into:

• Point of Care
• Laboratory Testing

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The regional markets for cardiac biomarkers can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Increasing Prevalence of Critical Heart Conditions to Drive the Market Growth of Cardiac Biomarkers

The pandemic bolstered the market for cardiac biomarkers due to the impact of COVID 19 on cardiovascular systems, which led to the rising application of biomarkers in diagnosis and treatment. The increasing cases of cardiac diseases worldwide due to unhealthy lifestyle changes are providing impetus to the market development of cardiac biomarkers. As per the World Health Organisation estimates, approximately 17.9 million people died from cardiovascular diseases in 2019, representing 32% of overall global deaths. The growing awareness about the reliable diagnosis that cardiac biomarkers offer to prevent heart diseases and the developing healthcare infrastructure play a critical role in expanding the market of cardiac biomarkers. The government initiatives to improve the diagnosis and treatment of cardiovascular diseases and the rising approvals of biomarker tests by organisations like the United States Food and Drug Administration is also invigorating the market of cardiac biomarkers. The increasing diagnostic tests offered by market players and the rapid development of novel biomarker tests to support clinicians in cardiac risk identification are expected to augment the market over the forecast period.

Key Players in the Global Cardiac Biomarkers Market

The report gives a detailed analysis of the following key players in the global cardiac biomarkers market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• F. Hoffmann-La Roche Ltd
• Beckman Coulter, Inc.
• Creative Diagnostics
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

Cardiac Biomarkers Market Report Snapshots

Cardiac Biomarkers Market Size

Cardiac Biomarkers Market Companies